Literature DB >> 18203326

Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity.

György Kerekes1, Zoltán Szekanecz, Henriett Dér, Zsuzsa Sándor, Gabriella Lakos, László Muszbek, István Csipö, Sándor Sipka, Ildikó Seres, György Paragh, János Kappelmayer, Edit Szomják, Katalin Veres, Gyula Szegedi, Yehuda Shoenfeld, Pál Soltész.   

Abstract

OBJECTIVE: Cardiovascular disease is a leading cause of mortality in rheumatoid arthritis (RA). Endothelial dysfunction often precedes manifest atherosclerosis. We assessed endothelial dysfunction and atherosclerosis in RA in context with laboratory markers.
METHODS: Fifty-two patients with RA and 40 matched healthy controls were studied. We assessed common carotid intima-media thickness (ccIMT) and flow- (FMD) and nitroglycerine-mediated vasodilation (NMD). We also assayed numerous immunological and metabolic laboratory markers.
RESULTS: FMD was significantly lower in RA (5.32% +/- 4.66%) compared to controls (8.30% +/- 3.96%) (p = 0.001). NMD was preserved in RA. ccIMT was significantly greater in patients with RA (0.63 +/- 0.14 mm) versus controls (0.54 +/- 0.15 mm) (p = 0.012). In patients with RA, ccIMT correlated with FMD% (R = -0.318, p = 0.022), age (R = 0.831, p < 0.001), and anti-dsDNA levels (R = 0.463, p = 0.006). FMD% correlated with serum interferon-gamma (IFN-gamma) levels (R = 0.516, p = 0.014). NMD% correlated inversely with the percentage of Th0 lymphocytes (R = -0.636, p = 0.006), serum immune complex (R = -0.692, p < 0.001), and IgM levels (R = -0.606, p = 0.003). Patients with RA were divided as "low" (< 0.65 mm) versus "high" (> 0.65 mm) ccIMT groups, and into "normal" (> 5%) versus "impaired" (< 5%) FMD% subsets. Low and high ccIMT groups differed significantly in age and serum interleukin 1 (IL-1) and anti-dsDNA levels. RA patients with normal versus impaired FMD% differed significantly in age, disease duration, and serum IFN-gamma levels. Lipoprotein(a) [Lp(a)] also correlated with rheumatoid factor (RF) and C-reactive protein (CRP); homocysteine (HCy) correlated with CRP and correlated inversely with folate and vitamin B12 production. Paraoxonase-1 (PON-1) activity correlated with serum tumor necrosis factor-alpha(TNF-alpha) and IL-6 levels.
CONCLUSION: This was a well characterized RA population, where FMD and ccIMT were impaired, indicating early endothelial dysfunction and accelerated atherosclerosis, respectively. RA-related autoimmune-inflammatory mechanisms and metabolic factors including anti-CCP, RF, CRP, circulating immune complexes, IgM, TNF-alpha, IL-6, Th0/Th1 ratio, HCy, folate, vitamin B12, and PON-1 may all be involved in the development of vascular disease in RA. Although ccIMT and FMD, as well as some laboratory factors, have been assessed by other investigators in RA-associated atherosclerosis, our results regarding the possible involvement of anti-CCP, anti-dsDNA, Lp(a), some cytokines, and PON-1 activity are novel. Early determination of FMD% and ccIMT may be useful to assess RA patients with high cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18203326

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  66 in total

1.  Relationship between pulse wave velocity and serum YKL-40 level in patients with early rheumatoid arthritis.

Authors:  Aysegul Kucukali Turkyilmaz; Gul Devrimsel; Aynur Kirbas; Yuksel Cicek; Murat Karkucak; Erhan Capkin; Ferhat Gokmen
Journal:  Rheumatol Int       Date:  2013-06-25       Impact factor: 2.631

2.  Assessment of cognitive function in female rheumatoid arthritis patients: associations with cerebrovascular pathology, depression and anxiety.

Authors:  Csaba Oláh; Zsófia Kardos; Mónika Andrejkovics; Enikő Szarka; Katalin Hodosi; Andrea Domján; Mariann Sepsi; Attila Sas; László Kostyál; Katalin Fazekas; Ágnes Flórián; Katalin Lukács; Ágnes Miksi; Zsuzsanna Baráth; György Kerekes; Márta Péntek; Attila Valikovics; László Tamási; Dániel Bereczki; Zoltán Szekanecz
Journal:  Rheumatol Int       Date:  2019-09-25       Impact factor: 2.631

3.  A prospective, longitudinal monocentric study on laser Doppler imaging of microcirculation: comparison with macrovascular pathophysiology and effect of adalimumab treatment in early rheumatoid arthritis.

Authors:  László Dávida; Vanda Pongrácz; Emir Awad Mohamed; Szilvia Szamosi; Gabriella Szücs; Andrea Váncsa; Orsolya Tímár; Zoltán Csiki; Edit Végh; Pál Soltész; Zoltán Szekanecz; György Kerekes
Journal:  Rheumatol Int       Date:  2019-12-19       Impact factor: 2.631

Review 4.  Cardiovascular risk and the use of biologic agents in rheumatoid arthritis.

Authors:  Debbie T Lim; Amy C Cannella; Kaleb D Michaud; Ted R Mikuls
Journal:  Curr Rheumatol Rep       Date:  2014-11       Impact factor: 4.592

Review 5.  A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis.

Authors:  Eduardo Nicolas Pollono; Maria A Lopez-Olivo; Juan Antonio Martinez Lopez; Maria E Suarez-Almazor
Journal:  Clin Rheumatol       Date:  2010-04-10       Impact factor: 2.980

Review 6.  The role of endothelial function and its assessment in rheumatoid arthritis.

Authors:  Faisel Khan; Bernat Galarraga; Jill J F Belch
Journal:  Nat Rev Rheumatol       Date:  2010-03-30       Impact factor: 20.543

Review 7.  Rheumatoid arthritis and cardiovascular disease.

Authors:  Mary Chester M Wasko
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

Review 8.  Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings.

Authors:  Hasya Zinger; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 9.  Vascular effects of biologic agents in RA and spondyloarthropathies.

Authors:  Zoltán Szekanecz; György Kerekes; Pál Soltész
Journal:  Nat Rev Rheumatol       Date:  2009-11-10       Impact factor: 20.543

Review 10.  Rheumatoid arthritis and metabolic syndrome.

Authors:  György Kerekes; Michael T Nurmohamed; Miguel A González-Gay; Ildikó Seres; György Paragh; Zsófia Kardos; Zsuzsa Baráth; László Tamási; Pál Soltész; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2014-08-05       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.